BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong

Prenetics and Prof. Dennis Lo Launch US$200m Joint Venture "Insighta" for Multi-Cancer Early Detection

- Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. - Insighta is powered by technology developed by the Centre for Novostics w...

June 26, 2023 | News

Brii Biosciences to Sell Equity Interest in Qpex Biopharma and Acquire Global Rights for BRII-693

Company acquires exclusive global rights of the novel lipopeptide BRII-693 for the difficult to treat MDR/XDR gram-negative bacterial infections &nbs...

June 26, 2023 | News

Sirnaomics Advances STP705 for SCCIS into Late-Stage Clinical Development

The FDA provided Sirnaomics guidance to move forward with late-stage clinical development because of the efficacious data provided as well as the widesprea...

June 20, 2023 | News

Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million

Based on its SBDD strategy, Viva Biotech has achieved remarkable growth in its CRO drug discovery and development business through its continuous effort th...

June 16, 2023 | News

Sirnaomics to Unveil GalAhead™ Therapeutic Platform Updates at Industry Conferences

The Company's first GalAhead™-based RNAi drug candidate, STP122G, has started a Phase I clinical trial in May 2023. The start of the trial indic...

June 14, 2023 | News

HKSH Medical Group and UCLA Health signed a Development Agreement

HKSH Medical Group (HKSH) and UCLA Health have signed a Development Agreement to strengthen their partnership in knowledge transfer in cancer management. T...

June 13, 2023 | News

Chinese Medical Development Led by Hong Kong Dragon's Medical and Reproductive Giants

Dragon's Medical successfully held its Advance Medical Technology Press Conference 2023 at W Hong Kong, signing strategic partnership agreements with ...

June 12, 2023 | News

Antengene's ATG-022 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers

Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases o...

May 24, 2023 | News

Antengene Clears U.S. IND for Phase I Trial of ATG-031 Antibody

- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncolog...

May 18, 2023 | News

Sirnaomics to Receive HK$8M Subsidy for Clinical Translational Catalyst Plan

The subsidy comes under HKSTP's Clinical Translational Catalyst ("CTC") programme dedicated to catalysing clinical translation to bring innovative, life-ch...

May 18, 2023 | News

Antengene Announces NDA Submission for XPOVIO® in Indonesia

"In just six months, we have submitted NDAs for XPOVIO® in three ASEAN countries, Malaysia, Thailand and Indonesia, supporting...

May 17, 2023 | News

International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment

The second International Healthcare Week (IHW), organised by the Hong Kong Trade Development Council (HKTDC) and supported by a wide range of healthcare se...

May 04, 2023 | News

Agilis Robotics tests animal trial for GI indication, aims 510(k) clearance by 2025 for improved endoscopic surgery.

The system by Agilis Robotics offers a novel combination of features that set it apart from conventional surgical robotic systems. With a remarkably compac...

April 19, 2023 | News

HUTCHMED's Fruquintinib NDA Accepted in China for 2nd-Line Gastric Cancer

Dr. Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED said, “The NMPA acceptance of our NDA for fruquintinib is a positive step towa...

April 18, 2023 | News

Stay Connected